Related Experiment Video
Updated: May 9, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental
1Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine, Great Neck, NY 11021, USA. hshah2@nshs.edu
Insights
Hepatitis C virus (HCV) infection can cause kidney disease like focal segmental glomerulosclerosis (FSGS). Pegylated interferon alfa-2a monotherapy achieved long-term remission in an adult patient with HCV-associated FSGS.
Area of Science:
- Nephrology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection is a global health concern and a known cause of chronic liver disease.
- HCV is associated with various glomerular diseases, including the rare focal segmental glomerulosclerosis (FSGS).
- Optimal treatment for HCV-associated FSGS remains unclear, with limited data on long-term outcomes of specific therapies.
Observation:
- A case study of an adult patient with HCV-associated FSGS presenting with nephrotic syndrome and renal failure.
- The patient received pegylated interferon alfa-2a monotherapy.
- Long-term follow-up data on the response to this treatment was assessed.
Findings:
- Treatment with pegylated interferon alfa-2a monotherapy led to a sustained virological response.
- The patient achieved clinical remission of nephrotic syndrome.
- Renal function was stabilized and remained so for five years post-treatment.
Implications:
- Pegylated interferon alfa-2a monotherapy may be an effective long-term treatment for HCV-associated FSGS.
- This finding offers a potential therapeutic strategy for patients with this rare kidney complication.
- Further research into HCV-associated glomerular diseases and their management is warranted.
Abstract:
Hepatitis C virus (HCV) infection is a global public health problem. Chronic HCV infection is an important cause of chronic liver disease. Since the first reported association between HCV and membranoproliferative glomerulonephritis (MPGN) in 1993, HCV has been described with other types of glomerular diseases, although less frequently. Focal segmental glomerulosclerosis (FSGS) is one such glomerular disease that has been rarely reported in association with HCV. Antiviral therapy with interferon and ribavirin has been shown to be beneficial in HCV-associated MPGN. The optimal therapy of HCV-associated FSGS is not currently known. To our knowledge, long-term response to pegylated interferon monotherapy in treatment of HCV-associated FSGS has not been reported. We report an adult patient with HCV-associated FSGS who presented with nephrotic syndrome and renal failure. Treatment with pegylated interferon alfa-2a monotherapy resulted in sustained virological response with a clinical remission of nephrotic syndrome and stabilization of renal function. Patient continued to remain in clinical remission of nephrotic syndrome with stable renal function, 5 years after treatment. We also briefly review the literature on HCV-associated glomerular diseases, particularly HCV-associated FSGS.
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
14:18Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Acute Kidney Injury III: Clinical Manifestations
Diabetic Nephropathy
Chronic Kidney Disease II: Clinical Manifestations